Causes and consequences of lipoprotein(a) abnormalities in kidney disease

被引:0
作者
Florian Kronenberg
机构
[1] Innsbruck Medical University,Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology
来源
Clinical and Experimental Nephrology | 2014年 / 18卷
关键词
Lipoprotein(a); Apolipoprotein(a); Genetics; Chronic kidney disease; Cardiovascular disease; Risk factor;
D O I
暂无
中图分类号
学科分类号
摘要
Lipoprotein(a) is one of the strongest genetically determined risk factors for cardiovascular disease, and patients with chronic kidney disease have major disturbances in lipoprotein(a) metabolism. Concentrations are increased and are influenced by glomerular filtration rate (GFR) and the amount of proteinuria. The reason for this elevation can be increased synthesis, as is the case for patients with nephrotic syndrome or those treated by peritoneal dialysis. In hemodialysis patients, a catabolic block is the reason for this elevation. The elevated concentrations might contribute to the tremendous cardiovascular risk in this particular population. In particular, the genetically determined small apolipoprotein(a) isoforms are associated with an increased risk for cardiovascular events and total mortality.
引用
收藏
页码:234 / 237
页数:3
相关论文
共 114 条
[1]  
Kronenberg F(2013)Lipoprotein(a)—resurrected by genetics J Intern Med 273 6-30
[2]  
Utermann G(1987)Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma J Clin Invest 80 458-465
[3]  
Utermann G(2009)Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 302 412-423
[4]  
Menzel HJ(1992)Apo(a) isoforms predict risk for coronary heart disease: a study in six populations Arterioscler Thromb 12 1214-1226
[5]  
Kraft HG(1991)Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups Hum Genet 86 607-614
[6]  
Duba HC(1996)Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease Arterioscler Thromb Vasc Biol 16 713-719
[7]  
Kemmler HG(2010)Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants J Am Coll Cardiol 55 2160-2167
[8]  
Seitz C(2008)A novel function of lipoprotein[a] as a preferential carrier of oxidized phospholipids in human plasma J Lipid Res 49 2230-2239
[9]  
Erqou S(2007)Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity and 10-year cardiovascular outcomes: prospective results from the Bruneck study Arterioscler Thromb Vasc Biol 27 1788-1795
[10]  
Kaptoge S(2006)Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck Study J Am Coll Cardiol 47 2219-2228